135 related articles for article (PubMed ID: 17524933)
1. An assay for the determination of sirolimus levels in the lymphocyte of transplant patients.
Masri M; Rizk S; Barbari A; Stephan A; Kamel G; Rost M
Transplant Proc; 2007 May; 39(4):1204-6. PubMed ID: 17524933
[TBL] [Abstract][Full Text] [Related]
2. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
3. The pharmacodynamic effect of sirolimus: individual variation of cytokine mRNA expression profiles in human whole blood samples.
Müller-Steinhardt M; Wortmeier K; Fricke L; Ebel B; Härtel C
Immunobiology; 2009; 214(1):17-26. PubMed ID: 19159823
[TBL] [Abstract][Full Text] [Related]
4. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
McAlister VC; Peltekian KM; Malatjalian DA; Colohan S; MacDonald S; Bitter-Suermann H; MacDonald AS
Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
Chueh SC; Wang SM; Lai MK; Chen J
Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
7. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
McAlister VC; Mahalati K; Peltekian KM; Fraser A; MacDonald AS
Ther Drug Monit; 2002 Jun; 24(3):346-50. PubMed ID: 12021624
[TBL] [Abstract][Full Text] [Related]
8. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
9. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
[TBL] [Abstract][Full Text] [Related]
11. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
van Hooff JP; Squifflet JP; Wlodarczyk Z; Vanrenterghem Y; Paczek L
Transplantation; 2003 Jun; 75(12):1934-9. PubMed ID: 12829890
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients.
Diekmann F; Fritsche L; Neumayer HH; Budde K
Kidney Blood Press Res; 2004; 27(3):186-90. PubMed ID: 15256816
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition and erythropoiesis: microcytosis or anaemia?
Diekmann F; Rovira J; Diaz-Ricart M; Arellano EM; Vodenik B; Jou JM; Vives-Corrons JL; Escolar G; Campistol JM
Nephrol Dial Transplant; 2012 Feb; 27(2):537-41. PubMed ID: 21785038
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus, a new, potent immunosuppressive agent.
Kelly PA; Gruber SA; Behbod F; Kahan BD
Pharmacotherapy; 1997; 17(6):1148-56. PubMed ID: 9399599
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury.
Fuller TF; Freise CE; Serkova N; Niemann CU; Olson JL; Feng S
Transplantation; 2003 Dec; 76(11):1594-9. PubMed ID: 14702530
[TBL] [Abstract][Full Text] [Related]
17. Clinical validation and implementation of a multiplexed immunosuppressant assay in dried blood spots by LC-MS/MS.
Sadilkova K; Busby B; Dickerson JA; Rutledge JC; Jack RM
Clin Chim Acta; 2013 Jun; 421():152-6. PubMed ID: 23473895
[TBL] [Abstract][Full Text] [Related]
18. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
[TBL] [Abstract][Full Text] [Related]
19. Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients.
Sampson VB; Dunn SP; Rymeski B; Malatack J; Rong NH; Flynn L; Krueger LJ
J Pediatr Surg; 2008 Jun; 43(6):1134-41. PubMed ID: 18558196
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus: its role in nephrology.
Lee VW; Chapman JR
Nephrology (Carlton); 2005 Dec; 10(6):606-14. PubMed ID: 16354246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
